Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | ENO1 | P06733 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | OTC | P00480 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3520934 | 0.80 | CA2 (0.43) | CA2CA4ENO1MEN1LMNA | |
| Pala SCHEMBL11121904 | 0.76 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| Pala SCHEMBL859680 | 0.76 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA | |
| SCHEMBL8399871 | 0.76 | PHF8 (0.41) | LMNAFOLH1 | |
| SCHEMBL7443684 | 0.76 | CTSC (0.42) | CA2CA4LMNATDP1 | |
| Pala SCHEMBL59449 | 0.74 | CA2 (1.00) | CA2CA4ENO1MEN1LMNA | |
| Sparfosic Acid SCHEMBL3514530 | 0.74 | CA2 (1.00) | CA2CA4ENO1MEN1LMNA | |
| SCHEMBL5061005 | 0.73 | FOLH1 (0.36) | CA2CA4MEN1LMNAHPGD | |
| SCHEMBL21724532 | 0.73 | HDAC3 (0.39) | MEN1KMT2A | |
| Pala SCHEMBL31389020 | 0.73 | CA2 (0.96) | CA2CA4ENO1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100310452-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2010-12-09 | — | — | US | disclosed |
| US-7399461-B2 | Prostate-specific membrane antigen and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2008-07-15 | — | — | US | disclosed |
| US-20040198657-A1 | Prostate-specific membrane antigen and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-10-07 | — | — | US | disclosed |
| US-20040001846-A1 | Prostate-specific membrane antigen and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-01 | — | — | US | disclosed |
| US-6569432-B1 | Isolated nucleic acid comprising a promoter sequence normally associated with the transcription of a gene encoding a human prostate-specific membrane antigen | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040001846-A1 | Prostate-specific membrane antigen and uses thereof | KLK3, ACP3, FOLH1 | CA2 1265/4885CA4 842/4885ENO1 739/4885 |
| US-20100310452-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND USES THEREOF | KLK3, ACP3, FOLH1 | CA2 1265/4885CA4 842/4885ENO1 739/4885 |
| US-20040198657-A1 | Prostate-specific membrane antigen and uses thereof | KLK3, ACP3, FOLH1 | CA2 1265/4885CA4 842/4885ENO1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.